CN105722519A - Composition containing a borage officinalis extract for alleviating, preventing, or treating metabolic diseases - Google Patents
Composition containing a borage officinalis extract for alleviating, preventing, or treating metabolic diseases Download PDFInfo
- Publication number
- CN105722519A CN105722519A CN201480061856.8A CN201480061856A CN105722519A CN 105722519 A CN105722519 A CN 105722519A CN 201480061856 A CN201480061856 A CN 201480061856A CN 105722519 A CN105722519 A CN 105722519A
- Authority
- CN
- China
- Prior art keywords
- present
- borage
- extract
- fat
- metabolic disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a composition containing a Borage officinalis extract for alleviating, preventing, or treating metabolic diseases and, more specifically, to a composition containing a Borage officinalis extract as an active ingredient for alleviating, preventing, or treating a metabolic disease selected from obesity, diabetes, dyslipidemia, fatty liver, and insulin resistance syndrome. The composition of the present invention exhibits excellent effects of inhibiting fat cell differentiation, reducing abdominal fat, and improving blood lipids.
Description
Technical field
On November 12nd, 2013 is set forth in the korean patent application 10-2013-0136877 CLAIM OF PRIORITY of Koran Office by the application, and the disclosure of above-mentioned application is as with reference to being inserted in this specification.
The present invention relates to the improvement of the metabolic disease comprising borage extract, prevention or therapeutic composition.
Background technology
Metabolic disease refer to occur because of chronic metabolic obstacle diabetes, hypertension, hyperlipemia, obesity, the simultaneous disease of multiple disease such as crown or arteriosclerosis, 1988 by Li Awen (Reaven) (ReavenGM, Diabetes, 1988,37:1595-1607) propose first.Metabolic disease is characterized by insulin resistance, hypertension, dyslipidemia, and major part is with overweight or fat.It was reported, metabolic disease or the risk factor of cardiovascular disease are relevant to the death caused by all reasons.It was reported, when Second-Type diabetics, high with the prevalence rate of the first diabetes mellitus type differently metabolic disease, it is known that when Second-Type diabetics is with metabolic disease, mortality rate increases (BonoraE, etal.DiabetMed., 2004,21:52-8；FordES, DiabetesCare., 2005,28:1769-78；AlexanderCM, etal.Diabetes, 2003,52:1210-1214).And, also deliver the correlational study (MykkanenL of the relatedness of each structural element of the big blood vessel of Second-Type diabetes and the metabolic disease of microvascular complication and hypertension, dyslipidemia etc., etal.Diabetologia., 1993,36:553-559；HaffnerSM, etal.Diabetes, 1992,41:715-722).
The most serious problem of metabolic disease is such as the generation (WolfSP-BrMedBull. of the chronic complicating diseases such as diabetic retinopathy, nephropathy, neuropathy, hyperlipemia, cardiovascular disease (apoplexy, angina pectoris, myocardial infarction, peripheral vascular disease), 1993,49:642-652).This chronic complicating diseases is most of once after occurring, carry out process through non-reversible, the method not intercepting this process till current completely, thus when unsuitable parallel treatment, causes that serious symptom makes patient lethal.Thus, in order to the metabolic disease with plyability symptom being carried out effectively management or treatment, it would be desirable, with the blood sugar decreasing effect for maintaining euglycemia, together there is the effect treating nephropathy, hepatopathy, hyperlipemia, but not yet develop this therapeutic agent till current, it is still necessary to individually take blood sugar lowering, depressor, cholesterol agent etc. extraly.
Borage (Borageofficinalis) is as the Rhizoma et radix valerianae starting to prefer to use from ancient Greek or Roman period, if drinking after flower or leaf are soaked in wine, can be removed that all griefs or worry make mood become happy and bright and clear, thus be referred to as " happy grass (cuphorosium) ".Especially, rich in mineral substances, calcium, potassium etc. in leaf, thus diuresis, paroxysmal pain alleviation, diaphoresis, purification, dermalaxia effect etc. are outstanding.According to nearest result of study, it was reported, rich in " gamma-Linolenic acid (strength) " in borage seed, thus before menstruation is come, the agitation of neural sensitivity, eczema or dermatosis are effective in cure.If leaf and flower are utilized as balneation agent, then not only making skin soften and cleaning skin, but also release the anxiety of body and mind, thus recently extracting oil from borage seed, being utilized as massage oil, cosmetic facial cream etc..
In this specification, have references to many sections of papers and patent documentation, and illustrate it and quote.Cited paper and the disclosure of patent documentation are entirely insertable in this specification as reference, thus level and the present disclosure of technical field belonging to the present invention are definitely described.
Summary of the invention
The problem solved
The present inventor can improve, prevent or treat the natural goods such as the metabolic disease (metabolicdisease) such as obesity, diabetes, dyslipidemia (dyslipidemia), fatty liver and insulin resistance syndrome (insulinresistancesyndrome) to develop and work hard.Its result, when processing borage extract, it is proposed that it has, and Adipocyte Differentiation reduces effect, abdominal cavity fat reduces effect and blood fat and improving effect, thus completing the present invention.
According to following detailed description of the invention, other purposes inventing the scope of claiming and the accompanying drawing definitely present invention and advantage.
The scheme of solution problem
According to an embodiment of the present invention, the present invention provides and comprises borage extract as the improvement of the metabolic disease of effective ingredient, prevention or therapeutic composition.
The present inventor can improve, prevent or treat the natural goods such as the metabolic disease such as obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome to develop and work hard.Its result, when processing borage extract, it is proposed that it has, and Adipocyte Differentiation reduces effect, abdominal cavity fat reduces effect and blood fat and improving effect.
When by borage extract-treated Extraction solvent being obtained the borage extract used in the compositions of the present invention, available multiple Extraction solvent.Preferably, available polar solvent or non-polar solven.What be suitable for as polar solvent is comprise (i) water, (ii) alcohol (being preferably methanol, ethanol, propanol, butanol, normal propyl alcohol, isopropanol, n-butyl alcohol, 1-amylalcohol, butoxy ethanol or ethylene glycol), (iii) acetic acid, (iv) dimethylformamide (DMFO, and (v) dimethyl sulfoxide (DMSO, dimethylsulfoxide) dimethyl-formamide).As non-polar solven be suitable for be comprise acetone, acetonitrile, ethyl acetate, methyl acetate, fluoric ether, pentane, hexane, 2,2,4-trimethylpentane, decane, hexamethylene, Pentamethylene., diisobutylene, 1-amylene, 1-chlorobutane, 1-chloropentane, o-Dimethylbenzene, diisopropyl ether, 2 cbloropropane isopropyl chloride, toluene, n-propyl chloride, chlorobenzene, benzene, diethyl ether, diethyl thioether, chloroform, dichloromethane, 1,2-dichloroethanes, aniline, diethylamine, ether, carbon tetrachloride and oxolane (THF, Tetrahydrofuran).
More preferably, the Extraction solvent utilized in the present invention is (a) water, (b) carbon number be 1～4 anhydrous or moisture lower alcohol (methanol, ethanol, propanol and butanol etc.), the mixed solvent of (c) above-mentioned rudimentary alcohol and water, (d) acetone, (e) ethyl acetate, (f) chloroform, (g) butyl acetate, (h) 1,3 butylene glycol, (i) hexane and (j) diethyl ether.Most preferably, the extract of the present invention is water, ethanol or their compositions-treated are obtained in borage.
An example according to the present invention, the borage extract of the present invention is the borage extract extracted by water, ethanol or their compositions.
As mentioned above, the term " extract " used in this manual has in the general meaning for crude extract (crudeextract) in the technical field of the invention, but also comprises the fraction that extract carries out fractional distillation (fractionation) in a broad sense.That is, borage extract not only comprises the borage extract utilizing said extracted solvent to obtain, and is also included in the borage extract that this additional purge process obtains.Such as, by making said extracted thing by having the ultrafilter membrane of the molecular weight cut-off value of regulation, the fraction obtained, based on the separation etc. of plurality of color spectrometry (in order to make based on size, electric charge, hydrophobicity, hydrophilic separation), the fraction obtained by adding the multiple purification process carried out also is contained in the borage extract of the present invention.
The borage extract utilized in the present invention can distill by reducing pressure and the additive proccess such as lyophilization or spray drying prepares powdered state.
In this manual, term " comprising as effective ingredient " refers to and fully realizes effect of following borage extract or the amount of activity.In the present invention, even if human body is also had no side effect by the compositions overdose extracted from the borage as natural plant material, thus the amount upper limit of the borage extract compositions that is contained in the present invention can be selected in suitable scope by general technical staff of the technical field of the invention and carry out.
The borage extract of the present invention can improve, prevent or treat the metabolic disease in the group of choosing freely obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome composition.
An example according to the present invention, above-mentioned dyslipidemia is hyperlipemia.
An example according to the present invention, above-mentioned insulin resistance syndrome comprises choosing freely based on more than one the insulin resistance syndrome in the group of the obesity of insulin resistance, hypertension, arteriosclerosis, hyperlipemia, hyperinsulinemia and non-alcoholic fatty liver disease composition.
The borage extract of the present invention reduces the differentiation of adipose cell.An example according to the present invention, above-mentioned borage extract makes the differentiation of adipose cell reduce 10～60%, 15～55% or 20～50%.
The borage extract of the present invention reduces the generation of neutral fat.An example according to the present invention, above-mentioned borage extract makes neutral fat reduce 20～60%, 30～50% or 35～45%.
The borage extract of the present invention increases the expression of adiponectin.An example according to the present invention, above-mentioned borage extract makes Messenger RNA (mRNA) the expression ratio matched group of adiponectin increase by 30～70%, 40～60% or 45～55%.
The borage extract of the present invention reduces the expression of leptin.An example according to the present invention, above-mentioned borage extract makes the Messenger RNA expression ratio matched group of leptin reduce 30～70%, 40～60% or 45～55%.
The borage extract of the present invention reduces abdominal cavity fat, the example according to the present invention, and above-mentioned borage extract makes the generation of abdominal cavity fat reduce 30～70%, 40～60% or 45～55% than matched group.
Above-mentioned abdominal cavity fat, as the meaning identical with interior fat, refers to the fat being positioned between tissue (such as, stomach, liver, kidney portion etc.) and in abdominal part.The subcutaneous fat (subcutaneousfat) of abdominal cavity fat and skin bottom and be positioned at the intramuscular fat (intramuscularfat) of skeletal muscle and have any different.The fat being positioned at the lower body of huckle and buttocks etc. is subcutaneous fat, and tissue does not have the interval of regulation, and on the contrary, abdominal cavity fat has the feature of substantially internal organs and half wriggling.Abdominal cavity fat is by mesentery (mesenteric), epididymis white fat tissue (epididymalwhiteadiposetissue；EWAT) and perirenal adipose tissue (perirenaldepot) fat depot (adiposedepot) composition.Abdominal cavity fat is considered fatty tissue, and in contrast, subcutaneous fat is not considered as fatty tissue.
The borage extract of the present invention reduces blood total cholesterol, blood neutral fat, blood free fatty and blood glucose.An example according to the present invention, above-mentioned borage extract, compared with matched group, reduces 10～50%, 20～40% or 25～35%, 45～85%, 55～75% or 60～70%, 30 70%, 40～60% or 45～55% and 10～60%, 12～55% or 14～50% respectively.
The borage extract of the present invention reduces blood pressure and rises.An example according to the present invention, above-mentioned borage extract reduces 2～20%, 3～18% or 5～15%.
The compositions of the present invention can provide into food compositions, functional food composite or pharmaceutical composition.
The compositions of the present invention can provide into food compositions.When the improvement of metabolic disease comprised in the group that borage extract forms as the free obesity of choosing of effective ingredient, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome of the present invention, prevention or therapeutic composition prepare into food compositions, as effective ingredient, not only comprise borage extract, also comprise usual added composition when preparing food, such as, protein, carbohydrate, fat, nutrient, flavoring agent and flavouring agent are comprised.As above-mentioned carbohydrate, for instance have as the glucose of monosaccharide, fructose etc., as the maltose of disaccharide, sucrose, oligosaccharide etc. and as the sugar alcohol of the common sugar of the dextrin of polysaccharide, cyclodextrin etc. and xylitol, Sorbitol and erythritol etc..As flavouring agent, natural flavours (Talin, Stevia rebaudiana (Bertoni) Hemsl extract (such as, rebaudioside A, glycyrrhizin etc.)) and synthesis flavouring agent (saccharin, aspartame etc.) can be used.Such as, when the food compositions of the present invention prepares into pick-me-up, except the borage extract of the present invention, also can comprise citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, Cortex Eucommiae extracting solution, Fructus Jujubae extracting solution, Radix Glycyrrhizae extract etc..
The present invention comprises borage extract and can be successfully prepared energy property food compositions as the improvement of metabolic disease in the group of choosing freely obesity of effective ingredient, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome composition, prevention or therapeutic composition.When the compositions of the present invention is successfully prepared energy property food compositions, comprise usual added composition when preparing food, for instance, comprise protein, carbohydrate, fat, nutrient and flavoring agent.Such as, when preparing into pick-me-up, as effective ingredient, except the extract of borage, also can comprise flavouring agent or natural carbohydrate.Such as, natural carbohydrate comprises monosaccharide (such as, glucose, fructose etc.), disaccharide (such as, maltose, sucrose etc.), oligosaccharide, polysaccharide (such as, dextrin, cyclodextrin etc.) and sugar alcohol (such as, xylitol, Sorbitol and erythritol etc.).Natural flavours (such as, Talin, Stevia rebaudiana (Bertoni) Hemsl extract etc.) and synthesis flavouring agent (such as, saccharin, aspartame etc.) can be used as flavouring agent.
The compositions of the present invention can prepare into pharmaceutical composition.
Preferred embodiment according to the present invention, the compositions of the present invention is the borage extract comprising (a) the invention described above；And (b) comprises the pharmaceutical composition of the carrier accepted on pharmaceutics.In the present invention, term " pharmaceutics effective dose " refers to the amount fully realizing above-mentioned borage extract effect or activity.
When the compositions of the present invention prepares into pharmaceutical composition, the pharmaceutical composition of the present invention comprises the carrier accepted on pharmaceutics.Be contained on the pharmaceutics in the pharmaceutical composition of the present invention accept carrier as preparation time commonly used material, comprise lactose, dextrose, sucrose, Sorbitol, mannitol, starch, arabic gum, calcium phosphate, alginate, gelatin, calcium silicates, microcrystalline Cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol, Talcum, magnesium stearate and mineral wet goods, but be not limited thereto.The pharmaceutical composition of the present invention also can comprise lubricant, wetting agent, sweeting agent, flavouring agent, emulsifying agent, suspending agent and antistaling agent etc. except mentioned component.The carrier being suitable for accepted on pharmaceutics and preparation are recorded in Remington'sPharmaceuticalSciences (19thed., 1995) in detail.
The pharmaceutical composition of the present invention can be administered or be administered in the way of parenteral in the way of oral, it is preferable that be suitable for Oral administration.
The dosage being suitable for of the pharmaceutical composition of the present invention can open multiple prescription according to factors such as preparation ways, administering mode, the age of patient, body weight, sex, condition of illness, diet, administration time, route of administration, drainage rate and reaction Irritability.The usual dosage of the pharmaceutical composition of the present invention is to be grown up as benchmark within the scope of 0.0001～1000mg/ days/kg.
The pharmaceutical composition of the present invention can pass through the method that general technical staff of the technical field of the invention easily implements, utilize the carrier accepted on pharmaceutics and/or excipient formulation to carry out such that it is able to prepare with the form of unit capacity or be built in multicapacity container and prepare.Now, dosage form is the form of the solution in oiliness or aqueous medium, suspension, syrup or emulsion, can be maybe the form of extractum, powder, powder, granule, tablet, capsule, also can comprise dispersant or stabilizer.
According to another embodiment of the present invention, the present invention provides the improvement of metabolic disease, prevention or Therapeutic Method, including comprising the borage extract compositions as effective ingredient and be administered into the step of object (subject).
The improvement of the metabolic disease of the present invention, prevention or Therapeutic Method utilize combinations of the above thing to carry out, thus in order to avoid this specification is excessively complicated, omit the common contents between them.
The effect of invention
Inventive feature and advantage are summarized as follows:
A () present invention provides and comprises borage extract as the improvement of the metabolic disease of effective ingredient, prevention or therapeutic composition, in the group of above-mentioned metabolic disease choosing freely obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome composition.
B the compositions of () present invention presents outstanding Adipocyte Differentiation inhibition, abdominal cavity fat reduces effect and blood fat and improving effect.
Accompanying drawing explanation
Fig. 1 illustrated by borage extract-treated after adipose cell, analyzed the result of cells survival rate at 24 hours, 48 hours and 72 hours.
Fig. 2 illustrates that the neutral fat (Triacylglycerol) of the adipose cell of processed borage extract is containing quantitative analysis result.
Fig. 3 illustrates that the Messenger RNA of the adiponectin (adiponectin) of the adipose cell of processed borage extract expresses the analysis result of degree.
Fig. 4 illustrates that the Messenger RNA of the leptin (leptin) of the adipose cell of processed borage extract expresses the analysis result of degree.
Fig. 5 illustrates and in the way of in the of 25, less than 50 men and women of 60 years old, is divided into 2 groups of picked-ups placebo (placebo) or the front/rear waistline of borage extract 19 one full year of life as object often organizing.
Detailed description of the invention
Hereinafter, the present invention is illustrated in greater detail by embodiment.These embodiments are served only for illustrating in greater detail the present invention, and according to idea of the invention, the scope of the present invention is not restricted to these embodiments, and this is apparent from for general technical staff of the technical field of the invention.
Embodiment
Embodiment 1: the preparation of borage extract
The mixing leaf of borage, flower and seed mix the purified water about 10 times of volumes and prepare mixed solvent, under 80 DEG C of Extracting temperature, repeatedly 5 times hot water extraction is carried out 6 hours after pulverizing.Filter this extract come vacuum concentration after, after 1:2 mixing borage and dextrin, carry out spray drying to obtain borage extract.
Embodiment 2: the activity analysis of borage extract
Confirm the Adipocyte Differentiation inhibition of the present composition and reduce effect by the interior fat of related lipid fat in cell, lipoprotein and hormone determination.
The differentiation inhibition of PECTORAL LIMB SKELETON 3T3-L1 cell
3T3-L1 cell as PECTORAL LIMB SKELETON (preadipocyte) is extensively utilized in the metabolic process of research adipose cell, also in cell cultivation process in the present invention, after treatment compositions, the differentiation of cell is more few, and obesity effect is more big.Utilize culture fluid, in the culture medium of supply 5% carbon dioxide, with 37 DEG C of temperature, 3T3-L1 cell is cultivated.Cell culture fluid uses the hyclone (FBS comprising 10%, fetalbovineserum) and antibiotic (antibiotics) Da Erbai kirschner improvement eagle culture medium (DMEM, Dulbecco'sModifiedEagle'sMedia).Every 2～3 days, utilize phosphate buffer (phosphatebufferedsaline, PBS) to clean after cultured cells surface, put into the trypsin trypsin of 0.5%), and process, carry out successive transfer culture by desorption cell.Cell culture fluid is replaced with the insulin (5 μ g/ml), the dexamethasone (dexamethasone that comprise as induction material；DEX, 0.25 μ Μ) and the induction culture fluid of MTX (l-methyl-3-methylxanthine, 0.5 μ Μ), cultivate 1～3 day, be adipose cell by cell induction.After cultivating 3 days, utilize the culture medium culturing containing only insulin after 2～3 days, be replaced by the culture fluid removing insulin.When the glucose assays experiment carried out to neutral fat inflow or glucose oxidation experiment, the 10th～12 day, the culture fluid containing low concentration (5mM) glucose is utilized to cultivate, the post processing borage extract of induction.Treated cell, after 24 hours, 48 hours and 72 hours, utilizes tetramethyl azo azoles salt (MTT, methylthiazolyltetrazolium) to analyze method, measures the quantity of the cell being attached to 96 orifice plates.Secondly, after processing borage extract, the differentiation 3T3-L1 cell of 10 days measures the amount of neutral fat (triacylglycerol), adiponectin (adiponectin) and leptin (leptin) respectively.
Represent result with meansigma methods and standard deviation, in order to significance test statistical disposition utilizes T inspection (Student'st-test), as p < 0.05, be considered notable.Fig. 1 to Fig. 4 represents result.
As can confirm that measurement result at Fig. 1, when processing borage extract, in 24 hours, 48 hours and 72 hours, respectively about 21%, 35%, 42%, cell quantity substantially reduces compared with matched group.
As can confirm that the change of the neutral fat based on this extract-treated in fig. 2, when by borage extract-treated 48 hours, in adipose cell, the amount of neutral fat presents the significant minimizing of about about 38% compared with matched group.And, after processing this extract, the relatively result of the Messenger RNA expression of adiponectin, as shown in Figure 3, in the Messenger RNA amount of adiponectin, when by borage extract-treated 48 hours, add the Messenger RNA expression of about about 1.5 times compared with matched group.
As Fig. 4 can confirm that, compare the result of the Messenger RNA expression after this extract-treated 48 hours, for the amount of leptin Messenger RNA, when processing borage extract, confirm the minimizing effect of about 0.49 times compared with matched group.
Embodiment 3: the visceral obesity of borage extract reduces effect and confirms
Using C57BL/6J mice as object, the compositions of the picked-up present invention, confirm that before and after picked-up, interior fat reduces effect, thus confirming interior fat to reduce effect.
Arbitrarily supply higher fatty acid/high sugar food (OrientalYeastCo. product) 8 weeks to 30 (female, 10 week old) C57BL/6J mices, induce into meals fat.Afterwards, in the way of often organizing 15, mice is divided into two groups, uses bread and cheese (OrientalYeastCo.) as the non-process group (matched group) of basic food and to utilize the group that the borage extract of preparation supplies dietary supplement to study.In two groups, make whole mice freely take food 4 weeks, after one night of going on a hunger strike after 4 weeks, under ether-Long Peng (ether-rompun)/Patients Under Ketamine Anesthesia, cut open the belly, from abdominal aorta blood-letting, massacre mice.Then, extract periuterine fat and perinephric fat is measured.It is recorded as intra abdominal fat amount by worthwhile for the weight of above-mentioned two-part fat together, represents its result in Table 1.
According to result, can confirm that as follows: in borage extract is absorbed constantly the mice of month, not only whole lose weight, and intra abdominal fat amount substantially reduces.Therefore, the interior fat being presented by the picked-up of higher fatty acid/high sugar food and accumulate is reduced by the picked-up containing borage extract.
Table 1
Embodiment 4: the diabetes mellitus prevention effect of borage extract confirms
Utilize as presenting heritability obesity and carrying out the KK-Ay mice of animal model of type 2 diabetes mellitus and confirm diabetes mellitus prevention effect and lipid metabolism improves effect.
In the way of often organizing 8, diabetic mice (female, 8 week old) is divided into two groups, uses bread and cheese to make matched group (non-process group) and borage extract-treated groups as basic food.In all groups, diabetic mice is made freely to take food 4 weeks.Borage extract is made an addition to bread and cheese in order to research by the ultimate density with 0.3%.
For during food, the body weight and the blood glucose that measure weekly mice represent in table 2, and blood glucose is from a small amount of blood of the tail vein collection of mice and utilizes simple blood testing equipment to measure blood glucose.
After terminating during food, make mice go on a hunger strike after one night, under ether-Long Peng/Patients Under Ketamine Anesthesia, cut open the belly, from abdominal aorta blood sampling and remove liver and be measured.Further, National Central University of Korea S clinical case subject is entrusted to analyze the T-CHOL (Total-Cholesterol in above-mentioned blood；T-CH0), triglyceride (Triglyceride；TG), free fatty (Non-esterifiedFattyAcid；NEFA), glutamic oxaloacetic transaminase, GOT (GOT, GlutamicOxaloaceticTransaminase), glutamate pyruvate transaminase (GPT, GlutamicPyruvateTransaminase), leucine aminopeptidase (LAP, LiverActivatorProtein), acetylcholine esterase (Cholinesterase；ChoE), gross protein (TP-S) and albumin (ALB-S).
Table 2 is the result of the body weight change during 4 weeks of confirmation mice.When processing the experimental group of borage extract, the average weight of mice is more inconspicuous than what matched group increased, starts to confirm the significant minimizing of more than 4g from borage extract after absorbing 3 weeks.Display in the data representing blood glucose, after the extract of picked-up borage, started to present significant blood glucose than matched group after 2 weeks and reduces.This is as the process of time, when being absorbed 4 weeks by borage extract, presents the blood glucose minimizing effect of about more than 200mg/cW than matched group when the 4th week.This is to mean that extract suppresses blood glucose to rise effectively.
Table 2
Table 3 is the result illustrating liver weight and blood test data.Represent according to result, for the toxicity such as liver weight, glutamic oxaloacetic transaminase, GOT and glutamate pyruvate transaminase, the group of comparative control group and picked-up borage extract, all do not present statistically difference.This indicates that borage extract has no hepatotoxic result.On the other hand, in the diabetic mice of picked-up borage extract, T-CHOL, triglyceride and free fatty do not present the minimizing statistically significantly of about 29%, 65%, 49% than comparison component.This is to mean that borage extract is by lipid metabolism improvement result, can reduce hyperlipidemia.
Table 3
Being represented by the above results, borage extract not only has blood glucose rising inhibitory action and the effect of losing weight, and also has lipid metabolism improvement result.
Embodiment 5: the hypertension prevention effect of borage extract
Use along with the aging spontaneous hypertensive rat (SpontaneouslyHypertensiveRat as hypertension animal model bringing out hypertension；SHR) resisting hypertension effect of borage extract is confirmed.
In the way of often organizing 10, rat (male, 6 week old) is divided into two groups, and is divided into the matched group absorbing common basic diet and the picked-up group containing borage extract to test.In order to bring out hypertension, in matched group, process 3ml/kg propylene glycol every day, in the extract group of borage, with the dosage of 30mg/3ml/kg/ days, propylene glycol mixes borage extract and absorbs.Altogether confirm blood pressure reduction effect by the mode of oral administration in 4 weeks.Make rat freely absorb remaining to take food and water.
Process and start the previous day day and process latter 7 days, 14 days, 21 days, 28 days, utilize noinvasive automatic blood pressure determinator to determine the blood pressure of caudal artery.Blood pressure determination was carried out before each sample is administered.Represent blood pressure data in table 4.Being 115mgHg starting the blood pressure before administration, each group is all equivalent to regime values.When matched group, processing latter 7 days, blood pressure begins to ramp up, and hypertension occurs.But, when processing borage extract, being differently viewed, with matched group, the phenomenon suppressing blood pressure to rise, the 14th day, the 21st day and the 28th day starts to present significant difference compared with matched group, within 28 days, observes the blood pressure drops phenomenon of about about 12% upon administration.
Table 4
Embodiment 6: improve effect by the weight regulation of human trial and obesity
Make men and women absorb the compositions of the present invention, confirm body-weight regulator obesity improve effect by body weight change and body fat measuring before and after absorbing.
Object of study and period
In the way of often organizing arrangement 25, will have agreed to 19 one full year of life of this inspection is arbitrarily categorized as the matched group (placebo) of picked-up placebo and the experimental group of mixture (8:2 mixing ratio) of this extract of picked-up less than 50 men and women (male 22, women 28) of 60 years old, by placebo or experimental drug, by every day, the amount of 400mg is absorbed 4 weeks.Body Mass Index (Body-MassIndex is have selected as experimenter；BMI) it is the people of more than 23 or people that abdominal circumference is man 90cm, woman more than 80cm.Before picked-up and after picked-up, by height, body weight, Body Mass Index, waistline, blood pressure, pulse, body composition (body fat rate and fat free body weight-impedance method) and blood test, measure high density lipoprotein (HDL)-T-CHOL, neutral fat and T-CHOL etc., by absorbing borage compositions, have rated the syndromic prevention of metabolic disease risk factor and improve effect.
Body Mass Index (Body-MassIndex)
In table 4, representing the borage extract picked-up group of the present invention and Body Mass Index (BMI) result of blank group, end value is charged to average and standard brick deviation, and statistical disposition utilizes T to check, p < O.05 time, be considered notable.
Result of the test, the Body Mass Index of matched group is without too big difference before and after picked-up, and on the contrary, this compositions picked-up group presents Body Mass Index compared with before picked-up and substantially reduces about 2.4kg/m2.Thus the minimizing of logical Body mass index presents the compositions scalable of the present invention or improves fat or overweight.
Table 5
Waistline
In Figure 5, representing the borage extract picked-up group of the present invention and the waistline of blank group, end value is charged to average and standard deviation, and statistical disposition utilizes T to check, and when p < 0.05, is considered notable.
Result of the test represents, the waistline of matched group is in the picked-up too big difference of front/rear nothing, and on the contrary, the picked-up group of borage extract observes that Body Mass Index substantially reduces about 3.98cm compared with before picked-up.Present the compositions of the present invention thereby through the minimizing of waistline to prevent or improve stomach fat and increase.
Above, the specific part of present invention being described in detail, this detailed technology is pertaining only to preferred embodiment, and the scope of the present invention is not limited to this, and this is apparent from for general technical staff of the technical field of the invention.Therefore, the substantial scope of the present invention should define according to the appended claimed scope of invention and its equivalent technical solutions.
Claims (9)
1. the improvement of a metabolic disease, prevention or therapeutic composition, it is characterised in that comprise borage extract as effective ingredient.
2. compositions according to claim 1, it is characterised in that above-mentioned metabolic disease is the metabolic disease in the group of choosing freely obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome composition.
3. compositions according to claim 1, it is characterised in that above-mentioned dyslipidemia is hyperlipemia.
4. compositions according to claim 1, it is characterized in that, above-mentioned insulin resistance syndrome comprises choosing freely based on more than one the insulin resistance syndrome in the group of the obesity of insulin resistance, hypertension, arteriosclerosis, hyperlipemia, hyperinsulinemia and non-alcoholic fatty liver disease composition.
5. compositions according to claim 1, it is characterised in that the improvement of above-mentioned metabolic disease, prevention or therapeutic composition are food compositions, functional food composite or pharmaceutical composition.
6. the improvement of a metabolic disease, prevention or Therapeutic Method, it is characterised in that include to comprise the borage extract compositions as effective ingredient and be administered into the step of object.
7. method according to claim 6, it is characterised in that above-mentioned metabolic disease is the metabolic disease in the group of choosing freely obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome composition.
8. method according to claim 6, it is characterised in that above-mentioned dyslipidemia is hyperlipemia.
9. method according to claim 6, it is characterized in that, above-mentioned insulin resistance syndrome comprises choosing freely based on more than one the insulin resistance syndrome in the group of the obesity of insulin resistance, hypertension, arteriosclerosis, hyperlipemia, hyperinsulinemia and non-alcoholic fatty liver disease composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130136877A KR101620077B1 (en) | 2013-11-12 | 2013-11-12 | Composition for Improving, Preventing or Treating Metabolic Diseases comprising Extracts from Borage officinalis |
| KR10-2013-0136877 | 2013-11-12 | ||
| PCT/KR2014/010132 WO2015072674A1 (en) | 2013-11-12 | 2014-10-27 | Composition containing a borage officinalis extract for alleviating, preventing, or treating metabolic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105722519A true CN105722519A (en) | 2016-06-29 |
Family
ID=53057579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480061856.8A Pending CN105722519A (en) | 2013-11-12 | 2014-10-27 | Composition containing a borage officinalis extract for alleviating, preventing, or treating metabolic diseases |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP6220081B2 (en) |
| KR (1) | KR101620077B1 (en) |
| CN (1) | CN105722519A (en) |
| WO (1) | WO2015072674A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108432924A (en) * | 2018-06-08 | 2018-08-24 | 贵州玉屏展鸿茶叶有限公司 | A kind of health protection tea of prevention diabetes |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014103475A1 (en) | 2012-12-27 | 2014-07-03 | 株式会社林原 | Skin-exterior anti-ageing composition and production method therefor |
| US10426806B1 (en) * | 2018-06-13 | 2019-10-01 | Muhammad Iqbal Choudhary | Anti-obesity effect of Borago officinalis linn. extracts to prevent and treat metabolic disorders |
| KR102193317B1 (en) * | 2019-03-12 | 2020-12-22 | 주식회사 엔에스웰니스 | Composition for obesity treatment and improvement |
| KR102238430B1 (en) * | 2019-05-29 | 2021-04-09 | 한국식품연구원 | A composition for improving, preventing and treating obesity and metabolic disease comprising polysaccharide fraction isolated from barley leaf |
| KR20220037997A (en) | 2020-09-18 | 2022-03-25 | 서울대학교산학협력단 | Pharmaceutical composition for preventing or treating metabolic disease containing dimethylchalcone |
| KR20230135001A (en) | 2022-03-15 | 2023-09-22 | 중앙대학교 산학협력단 | Novel dimethylchalcone derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776463A (en) * | 1997-02-19 | 1998-07-07 | Arginteanu; Ronit | Method of reducing stress and circulatory heart disease with freeze-dried borage petal extracts |
| JPH11322628A (en) * | 1998-05-12 | 1999-11-24 | Fukiya Tadashi | External preparation for skin |
| KR20040052904A (en) * | 2004-05-13 | 2004-06-23 | 약초나라(주) | Products and herbal extract composition effective on the lowering for blood cholesterol and triglycerides |
| CN101978949A (en) * | 2010-11-16 | 2011-02-23 | 王京南 | Gamma-linolenate fat emulsion intravenous injection and preparation method thereof |
-
2013
- 2013-11-12 KR KR1020130136877A patent/KR101620077B1/en active IP Right Grant
-
2014
- 2014-10-27 JP JP2016553186A patent/JP6220081B2/en not_active Expired - Fee Related
- 2014-10-27 WO PCT/KR2014/010132 patent/WO2015072674A1/en active Application Filing
- 2014-10-27 CN CN201480061856.8A patent/CN105722519A/en active Pending
Non-Patent Citations (7)
| Title |
|---|
| （美）尼古拉斯.裴利康: "《美丽健康与长寿的7大秘密 细胞新生的奇迹》", 31 December 2010, 黑龙江科学技术出版社 * |
| ANWARUL HASSAN GILANI ET AL: "Pharmacological basis for the use of Borago officinalis in gastrointestinal,respiratory and cardiovascular disorders", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
| MARZENA PIESZAK ET AL: "Borage (Borago officinalis L.)-a valuable medicinal plant used in herbal medicine", 《HERBA POLONICA》 * |
| 刘荣奇: "《健康排毒全典》", 31 December 2006, 北京：海潮出版社 * |
| 李少丹: "《规范化力量训练》", 31 December 2008 * |
| 蔡秀成等: "琉璃苣油对脂质代谢和脂质过氧化的影响", 《中国药理学通报》 * |
| 马学毅等: "《糖尿病自我防治》", 31 December 2004, 北京：金盾出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108432924A (en) * | 2018-06-08 | 2018-08-24 | 贵州玉屏展鸿茶叶有限公司 | A kind of health protection tea of prevention diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6220081B2 (en) | 2017-10-25 |
| JP2016537422A (en) | 2016-12-01 |
| KR20150054439A (en) | 2015-05-20 |
| KR101620077B1 (en) | 2016-05-12 |
| WO2015072674A1 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105722519A (en) | Composition containing a borage officinalis extract for alleviating, preventing, or treating metabolic diseases | |
| JP2021501119A (en) | Visceral fat obesity prevention, amelioration or therapeutic composition containing Danshen extract | |
| CN114096657A (en) | New fecal bacillus pusillus strain EB-FPDK11 and application thereof | |
| KR101501233B1 (en) | Pharmaceutical composition or health food containing black tea ethanol solution extracts which is effective for reducing body weight and body fats or preventing or treating lipid related metabolic disease | |
| KR20120112137A (en) | Composition containing ethylacetate fraction of schisandra chinensis baillon or wuweizisu c isolated from the same for treating or preventing obesity | |
| KR20160099963A (en) | Pharmaceutical composition for prevention or treatment of obesity comprising the extracts of Schizandra chinensis as active ingredient | |
| JP5819209B2 (en) | Differentiation promoter from stem cells to brown adipocytes | |
| CN104055947A (en) | Traditional Chinese medicine composition comprising grape extract products and preparation method thereof | |
| KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
| WO2018074831A1 (en) | Composition for preventing or treating obesity containing ethanolic extract of r a mulus mori | |
| US10183048B2 (en) | Composition for promoting the activity of peroxisome proliferator-activated receptor-delta | |
| KR20200012363A (en) | Composition for preventing, ameliorating or treating obesity comprising Heracleum moellendorffii root and Torilis japonica mixed extract as effective component | |
| KR101851639B1 (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
| KR102236685B1 (en) | Composition for preventing or treating lipid metabolism diseases comprising extract of salvia miltiorrhiza or paeonia lactiflora | |
| CN108404088B (en) | Traditional Chinese medicine for treating type II diabetes and preparation method thereof | |
| EP3750546A1 (en) | Glycerol release promoter | |
| JP4809611B2 (en) | Fat cell fat accumulation inhibitor | |
| KR100895500B1 (en) | Composition for the prevention and treatment of fatty liver diseases containing honokiol as an active ingredient | |
| KR101689513B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Stemonae Radix extract as effective component | |
| JP6513404B2 (en) | Fat burning promoter and hypothermia improving agent | |
| CN110404029B (en) | Composition with blood sugar reducing effect and preparation method and application thereof | |
| JP5864003B1 (en) | Novel Rakan fruit extract composition having lipid accumulation inhibitory effect | |
| CN112812127B (en) | C20-diterpene alkaloid compound and preparation method and application thereof | |
| JP2017206477A (en) | Myogenesis promoting composition | |
| KR20140100134A (en) | Composition for preventing and treating type ii diabetes mellitus containing piperis longi fructus extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160629 |
|
| WD01 | Invention patent application deemed withdrawn after publication |